Arena Lays Out Path Forward For Lorcaserin
This article was originally published in The Pink Sheet Daily
Executive Summary
Arena Pharmaceuticals and Japanese partner Eisai plan to resubmit an NDA for the controversial obesity drug lorcaserin by the end of 2011.
You may also be interested in...
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.
Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin
The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.
FDA Issues Complete Response Letter for Arena's Lorcaserin
Concerrns Raised by Advisory Committee Come Back to Haunt Lorcaserin, the company's first product to go through regulatory process.